These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 24771277)

  • 21. [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].
    Ji MM; Shen YG; Gong JC; Tang W; Xu XQ; Zheng Z; Chen SY; He Y; Zheng X; Zhao LD; Zhao WL; Wu W
    Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):112-117. PubMed ID: 36948864
    [No Abstract]   [Full Text] [Related]  

  • 22. A combination of low-dose cyclophosphamide and colony-stimulating factors is more cost-effective than granulocyte-colony-stimulating factors alone in mobilizing peripheral blood stem and progenitor cells.
    Meisenberg B; Brehm T; Schmeckel A; Miller W; McMillan R
    Transfusion; 1998 Feb; 38(2):209-15. PubMed ID: 9531956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.
    Micallef IN; Stiff PJ; Stadtmauer EA; Bolwell BJ; Nademanee AP; Maziarz RT; Partisano AM; Marulkar S; DiPersio JF
    Am J Hematol; 2013 Dec; 88(12):1017-23. PubMed ID: 23907769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents.
    Lerro KA; Medoff E; Wu Y; Seropian SE; Snyder E; Krause D; Cooper DL
    Bone Marrow Transplant; 2003 Dec; 32(12):1113-7. PubMed ID: 14647264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
    Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic evaluation of plerixafor addition in the mobilization and leukapheresis of hematopoietic stem cells for autologous transplantation: a systematic review.
    Mesquita Augusto Passos R; Feldens TK; Marcolino MAZ; Gouvêa AS; Dos Santos Oliveira L; Menardi Nasser L; Rodrigues RF; de Lourdes Martins Perobelli L; Campolina AG; de Almeida Neto C
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jan; 23(1):15-28. PubMed ID: 36285481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
    Spoerl S; Peter R; Wäscher D; Götze K; Verbeek M; Peschel C; Krackhardt AM
    Transfusion; 2017 Jan; 57(1):115-121. PubMed ID: 27859332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous Stem Cell Mobilization in the Age of Plerixafor.
    Cooper DL; Medoff E; Patel N; Baker J; Pratt K; Foss F; Seropian SE; Perreault S; Wu Y
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):411-6. PubMed ID: 27245311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
    Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.
    Cheng J; Schmitt M; Wuchter P; Buss EC; Witzens-Harig M; Neben K; Hundemer M; Hillengass J; Alexi R; Goldschmidt H; Chen BA; Ho AD; Schmitt A
    Transfusion; 2015 Feb; 55(2):275-83. PubMed ID: 25117969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
    Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A
    Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma.
    Desikan KR; Jagannath S; Siegel D; Nelson J; Bracy D; Barlogie B; Tricot G
    Leuk Lymphoma; 1998 Feb; 28(5-6):501-8. PubMed ID: 9613979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.
    Antar A; Otrock ZK; Kharfan-Dabaja MA; Ghaddara HA; Kreidieh N; Mahfouz R; Bazarbachi A
    Bone Marrow Transplant; 2015 Jun; 50(6):813-7. PubMed ID: 25751646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
    Smith VR; Popat U; Ciurea S; Nieto Y; Anderlini P; Rondon G; Alousi A; Qazilbash M; Kebriaei P; Khouri I; de Lima M; Champlin R; Hosing C
    Am J Hematol; 2013 Sep; 88(9):754-7. PubMed ID: 23749720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hematopoietic Progenitor Cell Counts of the Leukapheresis Product Determined Using Sysmex XN Analyzers Predict a Sufficient Number of CD34
    Imoto N; Kondo Y; Uchida K; Kurahashi S
    Intern Med; 2024 Jan; 63(2):189-195. PubMed ID: 37225486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
    Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Anderson LD; Bal S; Dhakal B; Nathwani N; Shah N; Medvedova E; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Schmidt T; Orlowski RZ; Shain KH; Cowan AJ; Dholaria B; Cornell RF; Jerkins JH; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG; Voorhees PM
    Transplant Cell Ther; 2023 Mar; 29(3):174.e1-174.e10. PubMed ID: 36494017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
    Costa LJ; Alexander ET; Hogan KR; Schaub C; Fouts TV; Stuart RK
    Bone Marrow Transplant; 2011 Jan; 46(1):64-9. PubMed ID: 20383210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure.
    Lefrère F; Mauge L; Réa D; Ribeil JA; Dal Cortivo L; Brignier AC; Aoun C; Larghéro J; Cavazzana-Calvo M; Micléa JM
    Transfusion; 2013 Mar; 53(3):564-9. PubMed ID: 22725259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
    Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
    J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
    Farina L; Spina F; Guidetti A; Longoni P; Ravagnani F; Dodero A; Montefusco V; Carlo-Stella C; Corradini P
    Leuk Lymphoma; 2014 Feb; 55(2):331-6. PubMed ID: 23656194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.